Nurix CSO Gwenn Hansen sells $36,982 in stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Chief Scientific Officer Gwenn Hansen sold 1,452 shares of common stock on September 1, 2026, for a total value of $36,982. The shares were sold at a price of $25.47 per share. The stock has since risen to $26.04, reflecting a remarkable 186% gain over the past year.

This transaction followed the exercise of employee stock options for 1,452 shares, which were acquired at a price of $1.86 per share, totaling $2,700. Both the option exercise and the subsequent sale were executed under a Rule 10b5-1 trading plan, which Ms. Hansen had previously adopted. The stock option had vested monthly beginning June 10, 2019, and was fully vested by May 10, 2023.

Following these transactions, Ms. Hansen directly holds 117,227 shares of Nurix Therapeutics common stock. She also directly holds 60,858 employee stock options. According to InvestingPro analysis, the stock appears undervalued at current levels, with analysts predicting the company will turn profitable this year. The platform offers 14 additional ProTips and comprehensive financial metrics for deeper analysis.

In other recent news, Nurix Therapeutics has seen several updates following its collaboration deal with Roche for bexdeg. Mizuho increased its price target for Nurix shares to $34 from $30, maintaining an Outperform rating, citing the transformative nature of the Roche deal and the company’s second-quarter 2026 earnings report. Truist Securities also raised its price target to $34 from $32, highlighting the partnership with Roche as a key factor in expanding value creation. Baird reiterated its Outperform rating with a $33 price target, noting that Nurix’s second-quarter results aligned with its earnings per share expectations. Meanwhile, Morgan Stanley adjusted its price target to $38 from $36, maintaining an Overweight rating based on growth potential. These developments underscore the positive sentiment among analysts regarding Nurix’s strategic moves and financial performance.